From static to dynamic SPECT/CT: A systematic review of clinical applications and perspectives.

Semin Nucl MedAug 6, 2026 (epub)
Clinical ResearchNuclear MedicineCardiologyNephrology

Gilles Metrard, Clara Cohen, Gilles Le Rouzic et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluates the clinical applications of dynamic SPECT/CT across various organ systems, particularly in cardiology and nephrology. It highlights that dynamic SPECT enables absolute myocardial blood flow quantification comparable to PET and assesses renal cortical function. The review synthesizes findings from 222 studies identified through a comprehensive literature search.

Key findings

  • Dynamic SPECT allows absolute myocardial blood flow quantification comparable to PET.
  • Renal applications of dynamic SPECT assess cortical function and excretory dynamics.
  • Technological advancements in CZT detectors and reconstruction algorithms enhance resolution.

Why it matters

Dynamic SPECT/CT represents a significant advancement in nuclear imaging, providing more detailed physiological insights that can improve diagnostic accuracy and patient management in various clinical settings.

Source

PubMed · PMID 42562661

Published in Semin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nuclear Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.